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Evaluation of the use of pharmacological treatment with prisoners experiencing high 
levels of hypersexual disorder 
 
Abstract  
This paper presents an evaluation of the impact of pharmacological treatment in 
reducing hypersexual disorder in adult males who have been incarcerated following 
conviction for a sexual offence. The evaluation compares two types of pharmacological 
treatment, one of which is part of the current NICE guidance for treatment of 
hypersexuality (Antiandrogens), whilst the other type (SSRIs) is off-label use in the UK 
for hypersexuality. The participant pool comprised 127 adult male prisoners serving 
sentences for sexual offences in a UK prison. Participants had been voluntarily referred 
for pharmacological treatment to manage hypersexual disorder. The results 
demonstrated a significant reduction of hypersexual disorder pre- and post-medication 
and contribute to the evidence base for the use of pharmacological treatment with 
individuals for whom hypersexual disorder may be a salient factor in their offending. 
Limitations of the current research are discussed. 
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Introduction  
In 2007, Her Majesty’s Prison and Probation Service (HMPPS) facilitated a pilot trial in a UK 
prison for people convicted of sexual offences (PCSOs), for the use of pharmacological 
treatment, or, as was consequently termed, medication to manage sexual arousal (MMSA). 
Guay (2009) and Grubin (2008a) had previously postulated that there was a promising role for 
medication with individuals convicted of sexual offences, with medication having been shown 
to reduce sexual urges and hypersexual behaviours in those with paraphilic and other sexual 
disorders. However, the evidence base has been lacking: the second Cochrane review, (Khan 
et al., 2015) to examine the effectiveness of pharmacological interventions for people 
convicted of sexual offences and those at risk of sexual offending, resulted in a final dataset 
of only seven studies (all published more than 20 years ago and mainly US-based and/or 
small studies), with no large scale or controlled evaluation studies. Their review, together 
with studies such as that by Turner, Basdekis-Jozsa and Briken (2012) of PCSOs in German 
forensic-psychiatric institutions, together with a preliminary evaluation by Winder et al. 
(2014) in a UK prison, indicated that pharmacological treatment is effective in helping 
prisoners to control their sexual urges, preoccupation and drive for sexual outlets. Further, it 
has been suggested that medication can reduce the risk of reoffending, especially when 
combined with psychological treatment (Kaplan & Krueger, 2010).  
 The importance of evaluating the effectiveness of pharmacological treatment to 
manage hypersexual disorder1 is centred on the strong association between sexual 
preoccupation and sexual recidivism in sex offending populations (Hanson & Harris, 2000; 
Beech, Fisher, & Ward, 2005). One dynamic measure of risk of recidivism most commonly 
used in the UK is the Structured Assessment of Risk and Need (SARN; Thornton, 2002). 
                                                 
1 Hypersexual disorder is being used throughout this paper to describe people who are experiencing high levels 
of sexual preoccupation, hypersexuality and/or sexual compulsivity (see Kafka, 2010 and 2014; Winder et al., 
2014, for more information on terminology). 
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Within this risk assessment, sexual preoccupation is termed ‘obsession with sex’, and this 
definition is used here as it incorporates Kafka and Prentky’s (1992) definition (which uses 
total sexual outlets as a measurement of sexual preoccupation) as well as using cognitive 
indicators. This captures all elements of sexual preoccupation, which is a limitation of the 
behavioural and cognitive only definitions. An obsession with sex has been seen to be the 
most strongly present ‘risk of reoffending’ factor in a study of over 1000 adult men serving 
prison sentences for a sexual offence (see Hocken, 2014). Yet, it is the only risk factor that is 
not addressed by current UK sex offending treatment programmes. Whilst the National 
Offender Management Service’s Healthy Sexual Functioning Programme (HSP) does address 
deviant arousal and promote healthy sexual functioning (HMPS, 2016), it does not actively 
help men struggling with sexual preoccupation, hypersexual behaviour or sexual 
compulsivity.  
The utility of pharmacological treatment, administered in the UK voluntarily to 
prisoners, has been declared a useful adjunct to traditional psychological treatment (Home 
Office, 2007; Guay, 2009; Turner, Basdekis-Jozsa & Briken, 2012). Qualitative research with 
sexually preoccupied prisoners by Lievesley, Elliott, Winder, Norman and Kaul (2014) has 
also helped to explain one of the mechanisms for this, with prisoner participants reporting 
more ‘headspace’ as a result of taking MMSA, helping them to focus better on the cognitive-
behavioural treatment programmes that they were undertaking. Having ‘headspace’ was 
particularly important, given that as part of the programmes prisoners are asked to describe 
their sexual offences in detail; sexually preoccupied individuals have reported that this can 
exacerbate their arousal, causing shame and embarrassment in group treatment (K. Hocken, 
personal communication, February 24, 2017). The reasons why individuals seek MMSA 
(along with concerns they may have), are described by Lievesley et al. (2014) in their 
qualitative exploration of prisoners’ experiences of SSRIs. Service users reported a reduction 
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in sexual preoccupation, sexual arousal and improvements in their abilities to manage 
negative emotions as they spoke about having “a clearer way of thinking: from sexually 
preoccupied to ‘human’” (Lievesley et al., 2014, p. 7). Service users typically recognised that 
their hypersexuality and sexual preoccupation were partly responsible for them committing a 
sexual offence (and thus being in prison), but they also reported high levels of distress, 
anxiety and/or depression, which they associated with their hypersexuality (and its 
consequences).  
 Three types of medication are available within the UK prison estate: Selective 
Serotonin Reuptake Inhibitors (SSRIs; Fluoxetine/Paroxetine), anti-androgens (AAs; 
Cyproterone Acetate; CPA) and gonadotropin-releasing hormone agonists (GnRH; 
Triptorelin). SSRIs increase levels of Serotonin, thereby inhibiting physiological and 
psychological arousal, erection and orgasm; they are reported to be especially effective in 
patients with obsessive-compulsive sexual deviance (Guay, 2009; Briken, Hill & Berner, 
2003; Bradford, 2001). Thibaut et al. (2010) argue, and the authors agree, that there is 
sufficient evidence for their successful use as an anti-libidinal medication, despite this not 
being a targeted use as set out by NICE guidelines. Moreover, there is evidence that SSRIs 
affect psychological factors that relate to sexual offending, namely (dis)inhibition of sexual 
behaviour, compulsive behaviours and compulsive thinking (Beech & Mitchell, 2005; Jordan, 
Fromberger, Stolpmann & Müller, 2011). 
On the other hand, AAs are recognised for their direct effect in reducing testosterone 
levels. Previous research has reported significant declines in hypersexuality, sexual 
preoccupation and/or sexual compulsivity in individuals treated with AAs (Bradford & 
Pawlak, 1993; Thibaut et al., 2010; Winder et al, 2014). Similarly, gonadotropin-releasing 
hormone agonists are used to constantly stimulate the pituitary gland, initially increasing but 
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ultimately decreasing pituitary secretion of luteinising hormone (LH) and thus diminishing 
testosterone release. 
 
Research Aims 
This research examined the hypothesis that there would be significant reductions in levels of 
hypersexual disorder (including sexual compulsivity and sexual preoccupation) for referred 
prisoners, pre- and post-medication. A further hypothesis postulated that reductions in 
hypersexual disorder pre and post medication would be demonstrated for both types of 
medication, that is, with (i) SSRIs and (ii) AAs. 
 
Method 
Participants 
Participants comprised 127 adult male individuals housed in a Category C UK prison for 
people with sexual convictions who had been referred for medication between 20102 and 
2016. The HMPPS criteria for referral comprise evidence of one or more of the following:  
‘a.   hyper-arousal (e.g., frequent sexual rumination, sexual preoccupation, difficulties in 
controlling sexual arousal, high levels of sexual behaviour), 
b.    intrusive sexual fantasies or urges, 
c.    subjective reports of experiencing urges that are difficult to control, 
d.    sexual sadism or other dangerous paraphilias such as necrophilia. Highly repetitive 
paraphilic offending such as voyeurism or exhibitionism’ (HMPS, 2008, pg. 3). 
 
Of the 127 men referred for treatment between 2010 (when medication was first offered to 
                                                 
2  Three individuals had been referred in 2009, but this was prior to the evaluation research; the majority of 
referrals were between 2010 and 2015 
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prisoners) and 2016, 75 received SSRIs (72: Fluoxetine; 3: Paroxetine), 16 received AAs 
(Cyproterone acetate, CPA), seven received a combination of SSRIs and AAs, two received a 
GnRH agonist (Triptorelin), 20 did not receive any medication (refused/not suitable) and 
seven prisoners were ‘on hold’ for the medication or they were undergoing assessment by the 
resident consultant psychiatrist for the medication. Therefore a total of 100 out of 127 
(78.74%) referred prisoners received medication.  
 
Medication 
Three types of medication were available: SSRI (Fluoxetine), AAs (Cyproterone Acetate, 
CPA) and gonadotropin-releasing hormone agonist (GnRH agonist; Triptorelin). Individuals 
typically commenced medication with a daily tablet of 20mg Fluoxetine, increasing to 
40/60mg as per the clinical judgement of the consulting psychiatrist. For more severe cases, 
or where the SSRIs did not appear to be working sufficiently in terms of reducing levels of 
hypersexual disorder (either in the view of the psychiatrist or the view of the patient and 
psychiatrist), AAs were prescribed. The typical starting dosage for AAs was 50mg, taken 
daily by tablet, with dosage increased to 100mg where the psychiatrist deemed this necessary 
and/or helpful. Dosages are in line with current guidelines for the treatment of paraphilic 
disorder (Thibaut et al., 2010) and the clinical judgment of the consulting psychiatrist. GnRH 
agonists were available, but were only used in two cases (due to the high cost of the 
medication) where release into the community was imminent and both prisoner and 
psychiatrist were concerned about an imminent risk of reoffending.  
 
Measures 
Data collated included: referral information, demographic and offending data, 
sentence information, and type and dosage of medication. IQ levels were sought from pre-
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existing Wechsler Adult Intelligence Scale (WAIS-IV; Wechsler, 2008) and Wechsler 
Abbreviated Scale of Intelligence (WASI-II; Wechsler, 2011) tests, carried out by trained 
psychologists. Static and dynamic risk data were also captured from pre-existing file 
information: static risk was recorded from Risk Matrix 2000 (RM2000; Thornton et al., 2003) 
and dynamic risk was reported from the Structured Assessment of Risk and Need (SARN; 
Thornton, 2002), and were carried out by trained psychologists. Data relating to several 
clinical measures (sexual preoccupation and hypersexual behaviour, described below) 
recorded by the psychiatrist were collated, with the additional psychometric measure; the 
Sexual Compulsivity scale (SCs; Kalichman et al., 1994a), collected independently by the 
research team from 2011 onwards.  
RM2000 
The RM2000 is a static actuarial risk tool used to assess the risk of recidivism for adult males 
with sexual convictions (Thornton, 2010; Thornton et al., 2003) and has shown good 
predictive accuracy for sexual recidivism (d = .74; Helmus, Babchisin & Hanson, 2013). The 
RM2000 generates a sexual risk and a violent risk score (scored as 1 [low], 2 [medium], 3 
[high] or 4 [very high]). Trained professionals within the prison use the tool as part of the 
treatment interventions; for this research those scores were obtained for participants from 
their psychology files.  
SARN 
The SARN is a dynamic risk tool used to identify dynamic risk factors for sexual offending 
and to understand individuals’ treatment needs (Thornton, 2002; Webster et al., 2006). The 
tool comprises 16 dynamic risk factors categorised into four domains; Sexual Interests, 
Distorted Attitudes, Socio-Affective Functioning and Self-Management. Each risk factor 
assesses risk within the individual’s offence chain, and in life generally (scored as 0 [not 
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present], 1 [present] and 2 [strongly characteristic]). As with the RM2000, the SARN is 
carried out by trained psychologists within the prison, as part of the treatment interventions, 
and the scores were obtained from participants’ psychology files. The SARN has been 
examined for its use with men with intellectual disability (ID) who commit sexual offences, 
and findings suggest the factors within it are applicable to understanding risk in this 
population (see Hocken, 2014). The SARN has not demonstrated predictive validity for risk 
in this population, however it is being used here to understand level of treatment need and not 
necessarily as a risk assessment tool. 
 
Sexual Compulsivity Scale (SC) 
The sexual compulsivity scale (SCs) was developed by Kalichman et al. (1994a) to assess 
insistent, intrusive, and uncontrolled sexual thoughts and behaviour. It is a 10-item scale with 
participants rating a series of statements using a four-point response scale ranging from 1 (not 
like me at all) to 4 (very much like me). Indicative items include: ‘my sexual thoughts and 
behaviours are causing problems in my life’ and ‘my desires to have sex have disrupted my 
daily life’. Cronbach’s alpha for the scale was 0.89 with a male sample, 0.92 with a female 
sample (Kalichman & Rompa, 2001), 0.89 with an HIV+ sample (Kalichman et al., 1994b) 
and 0.89 with an adult male prisoner sample (Winder et al., 2014). Cronbach’s alpha for the 
scale with the current sample was 0.83. This was also calculated for varying levels of IQ: with 
Chronbach alpha scores of .81 for the group with intellectual disability (IQ<70); .75 for the 
borderline IQ group (IQ= 71-80) and .93 for those above borderline IQ (IQ>81). 
The SCS was administered by a member of the research team in a one-to-one meeting 
with the participant. Due to the high proportion of participants with low IQ, the research team 
read questions aloud to all participants to standardise the procedure, and the participant gave 
their answer verbally from a four-point, colour-coded response card. The researchers also 
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ensured that each meeting did not last more than 45 minutes for those with an intellectual 
disability.   
 
Self-reported measures of sexual thoughts, feelings and behaviours.  
The measures reported below are those proposed by Grubin and others (see Grubin, 2008b).  
Hypersexual behaviour. Assessed by recording how many days in the past week participants 
self-reported as having masturbated to orgasm (0-7 days). 
Sexual Preoccupation (SP). Sexual preoccupation was assessed by the item ‘how much time 
do you spend thinking about sex?’ Responses were collated on a seven-point scale (1: Low 
[Very little]; 7: High [All the time]). Additional items relating to SP were ‘what is the 
strength of your sexual urges and fantasies?’ (1: Low; 7: High) and ‘what is your ability to 
distract yourself from sexual thoughts?’ (1: Easy; 7: Difficult). 
These measures are carried out by one prescribing psychiatrist who is part of the 
treatment team, meaning that potential bias is possible. However, the data was triangulated 
with the SCS (completed by the independent research team) and cross verification from both 
sources demonstrated similar results and thus validation of the data. A Pearson’s correlation 
revealed sexual compulsivity scores were significantly correlated with items relating to sexual 
pre-occupation within the clinical scores, such as the number of days engaged in sexual 
activity, r = 0.306, p=.018; the strength of sexual urges, r = 0.432, p<.001; and the ability to 
distract from sexual thoughts, r = 0.507, p<.001. 
Procedure 
Individuals who were perceived by prison staff (for example treatment facilitators) as having 
problems managing their sexual thoughts and behaviours were, with their consent, referred to 
prison healthcare. The psychiatrist assessed each referral, and where appropriate MMSA was 
prescribed. Participants continued to meet with the psychiatrist on a regular basis, and, at each 
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meeting, measures of hypersexual behaviour and sexual preoccupation were collated as part 
of the patient-psychiatrist consultation.  
Participants completed the sexual compulsivity measure (conducted by the research 
team) prior to commencing pharmacological treatment to establish baseline data, and every 
three months thereafter. Medical and offence related data were collated for each participant.  
Ethical approval for the research was obtained from a UK University and HMPPS 
ethics committee. Ethical protocols (informed consent, debrief and support to participants, 
withdrawal confidentiality of data) were followed. Since the data were not anonymised, they 
remained at all times within the prison establishment, maintained as per Prison Service Orders 
9020, 9015 and 1100. 
 
Statistical process and procedure 
Data from the various sources were inputted into Excel, and subsequently imported into SPSS 
v.22 for analysis. A one-way Repeated Measures ANOVA was conducted to explore changes 
in sexual compulsivity data. A series of Mixed Design ANOVAs were performed to explore, 
by type of medication (SSRIs vs AAs), potential changes (i) pre-medication, (ii) one month 
post-medication (iii) three months post-medication and (iv) six months post-medication across 
the clinical measures of hypersexuality. A MANOVA was carried out in order to explore the 
response to treatment in participants with ID and above average IQ. 
 
Results  
Sample Characteristics 
For the full sample (n=127) the mean IQ = 87.05 (SD = 16.00; 59-117, assessed by Wechsler 
Abbreviated Scale of Intelligence-Second Edition [WASI-II; Wechsler, 2011] or, where 
available for the individual, Wechsler Adult Intelligence Scale-Fourth Edition [WAIS-IV; 
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Wechsler, 2008]). Approximately half of the referral sample had ID or borderline ID (44% IQ 
< 80). Given this high percentage statistical analyses were broken down by IQ group for 
several of the measures to test for effects of IQ. 
 
In terms of ethnicity, all participants with available data were ‘White British’ with the 
exception of two ‘White Other’ and one ‘Black British Caribbean’. Two participants self-
identified as transgender women, though they are not undergoing any hormone treatment or 
medication for this. The mean age was 45.69 (SD = 14.48; 26-82). In terms of previous 
offences, the majority of participants had a history of previous sexual offences with a mean of 
2.99 previous sexual contact offences and 1.77 previous non-contact sexual offences per 
person. Referrals were serving a range of sentences: around 30% were serving a life or 
indeterminate public protection3 (IPP) sentence; and around 42% had a determinate sentence 
of between 1 and 14 years. There was no sentence length data for 28% of the participants.  
 
Data regarding treatment in sex offending treatment programmes (SOTPs) indicated that of 
the 84 (60%) participants with data, 83% (n=70) had completed an SOTP prior to medication 
(data were inputted on referral for medication). Static risk was reported from RM2000/S 
scores. The mean risk matrix score was high, with a mean of 3 and a mode of 4 (very high). 
Pre-treatment dynamic risk data were collated from SARN reports. The highest scoring 
dynamic risk factor was ‘sexual preoccupation’ (offence chain) with a mean of 1.92 and a 
mode of two. A score of two indicates the risk factor is strongly characteristic; thus, for this 
population, sexual preoccupation is a strong risk factor. This is closely followed by ‘poor 
                                                 
3 An indeterminate sentence for public protection was used to protect the public from serious offenders whose 
crimes did not warrant a life sentence. These were used between 2005 and 2012 in the UK and offenders are 
only released when the parole board deem them to be low enough in risk. A life sentence lasts for the whole of 
the person’s life, however they may be considered for parole at some point, but if they were to commit any 
other crime they would be returned to prison. 
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problem solving generally’ (M = 1.85, mode = 2), ‘sexual preoccupation generally’ (M = 
1.85, mode = 2), ‘lack of emotional intimacy generally’ (M = 1.84, mode = 2), ‘inadequacy 
generally’ (M = 1.56, mode = 2) and ‘sexual preference for children generally’ (M = 1.52, 
mode = 2). The lowest scoring dynamic risk factor was ‘adversarial sexual attitudes’ in the 
offence chain (M = 0.23, mode = 0) followed by ‘women are deceitful’ in the offence chain 
(M = 0.30 mode = 0). The other low scoring factors were ‘poor emotional control’ in the 
offence chain (M = 0.33, mode =0), and ‘sexualised violence’ in the offence chain (M = 0.36, 
mode = 0). 
 
Sexual compulsivity 
A one-way repeated measures ANOVA was conducted to compare scores of sexual 
compulsivity at T0 (pre-medication), T3 (three months) and T6 (six months) post-medication. 
The sample (n=33) comprised only those participants that continued to take medication for six 
months after their baseline date. This therefore excludes participants who withdrew consent 
within six months, those that left prison in this time and those that were no longer taking 
medication or those that stopped and re-started. As Figure 1 demonstrates, there was a 
significant effect for time, F(2,31) = 48.06, p = .001, multivariate partial eta-squared = .76. 
with scores reducing over time (see Figure 1). There was a significant reduction in scores 
between T0 and T3 F(1,31) = 55.15, p =.001 multivariate partial eta-squared = .63  and 
between T3 and T6 F(1,31) = 5.07, p = .03, multivariate partial eta-squared = .14.  
 
Figure 1: Mean Sexual Compulsivity Scores for participants taking medication to reduce 
sexual preoccupation: pre-medication (T0), three months’ post-medication (T3) and six 
months’ post-medication (T6). 
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A one-way ANOVA was conducted to explore the sexual compulsivity scores for varying 
levels of participant’s IQ. Results revealed no significant difference in scores between low IQ 
(M=2.7, SD=.34), borderline IQ (M=2.8, SD=.16), and above borderline IQ (M=2.6, 
SD=.11); F (2,51) =.545, p =.583. 
 
 
INSERT FIGURE 1 
 
 
Findings from clinical measures used to establish levels of sexual preoccupation and 
hypersexuality 
Analyses and graphs for participants’ scores on the clinical measures over three time periods 
are presented below. T0 represents the time before participants started taking medication; T1 
equates to approximately one month after participants started taking medication; T3 equates 
to approximately 3-4 months after participants started taking medication; and T6, six months’ 
post-medication. The sample (n=37) comprised only those participants that continued to take 
medication for six months after their baseline date. This excludes any participants who 
withdrew consent within six months, those that left prison in this time and those that are no 
longer taking medication or those that stopped and re-started. For the purposes of analysis, 
two groups are reported: (i) participants prescribed SSRIs and (ii) participants prescribed AAs 
(alone or in addition to SSRIs). The number of participants taking AAs alone was too low to 
be able to produce meaningful analysis. The three ANOVAs were conducted using 
Bonferroni adjusted alpha levels of .05/4 = .0125 per test to control for the familywise Type I 
error rate. 
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Clinical measure: Hypersexuality; Assessed as number of days masturbated leading to 
orgasm  
A mixed 2 X 3 ANOVA indicated a significant main effect of time (T0, T1, T3, T6) on 
hypersexuality, F(3,105) = 11.92, p = .001. Partial eta-squared = .254, with hypersexuality 
reducing over time (see Figure 2). Contrasts revealed that there was a significant decrease in 
hypersexuality between T0 (pre-medication) and T1 (one month post-medication), F(1,35) = 
11.63, p = .002. Partial eta-squared = .249.  
There was a significant effect of medication type (SSRIs, AAs), F (1,35) = 7.69, p = 
.009, with the AAs group presenting with significantly higher levels of sexual preoccupation. 
There was no interaction between medication type and time on level of sexual preoccupation, 
F(3,105) = 1.67, NS.  
 
Figure 2: Mean number of days masturbated in previous week for participants taking (i) 
SSRIs and (ii) AAs 
 
 
INSERT FIGURE 2 
 
 
Clinical measure: Sexual Preoccupation; Time spent thinking about sex 
A mixed 2 X 3 ANOVA indicated a significant main effect of time (T0, T1, T3, T6) on sexual 
preoccupation, F(3,108) = 16.07, p = .001 Partial eta-squared = .309, with sexual 
preoccupation reducing over time (see Figure 3). Contrasts revealed that there was a 
significant decrease in sexual preoccupation between T0 (pre-medication) and T1 (one month 
post-medication), F(1,36) = 19.75, p = .001. Partial eta-squared = .354.  
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There was no significant effect of medication type (SSRIs, AAs) on sexual 
preoccupation, F(1,36) = 6.20, p = .018. Partial eta-squared = .147. There was no interaction 
between medication type and time on sexual preoccupation, F(3,108) = 1.80, NS.  
Results from a MANOVA revealed no significant difference at T3 in time spent 
thinking about sex for varying levels of IQ, F (2,26) = 1.19, NS. 
 
 
Figure 3: Amount of time currently spent thinking about sex for participants taking (i) SSRIs 
and (ii) AAs 
 
 
INSERT FIGURE 3 
 
 
Clinical measure: Sexual Preoccupation; Strength of sexual urges 
A mixed 2 X 3 ANOVA indicated a significant main effect of time (T0, T1, T3, T6) on 
strength of sexual urges, F(3,108) = 18.75, p = .001 Partial eta-squared = .342 (see Figure 4).  
Contrasts revealed that there was a significant decrease in the inability to distract from sexual 
thoughts between T0 (pre-medication) and T1 (one month post-medication), F(1,36) = 17.79, 
p = .001. Partial eta-squared = .331.  
There was no significant effect of medication type (SSRIs, AAs) on strength of sexual 
urges, F (1,36) = 5.85, p = .021. Partial eta-squared = .14. There was no interaction between 
medication type and time on ability to distract from sexual thoughts, F(3,108) = 2.35, NS. 
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Figure 4: Strength of sexual urges for participants taking (i) SSRIs and (ii) AAs 
 
INSERT FIGURE 4 
 
 
Clinical measure: Sexual Preoccupation; Ability to distract from sexual thoughts 
A mixed 2 X 3 ANOVA indicated a significant main effect of time (T0, T1, T3, T6) on the 
individual’s ability to distract themselves from sexual thoughts, F(3,108) = 21.13, p = .001. 
Partial eta-squared = .370. Contrasts revealed that there was a significant decrease in the 
inability to distract from sexual thoughts between T0 (pre-medication) and T1 (one month 
post-medication), F(1,36) = 10.19, p = .003. Partial eta-squared = .221 (see Figure 5).  
There was a significant effect of medication type (SSRIs, AAs) on ability to distract 
from sexual thoughts, F (1,36) = 10.12, p = .003. Partial eta-squared = .219. There was an 
interaction between medication type and time on ability to distract from sexual thoughts, 
F(3,108) = 3.25, p = .024, partial eta-squared  = .083. 
Results from a MANOVA revealed no significant difference at T3 in ability to distract 
from sexual thoughts for varying levels of IQ, F (2,26) = 2.08, NS. 
 
Figure 5: Ability to distract from sexual thoughts for participants taking (i) SSRIs and (ii) 
AAs 
 
INSERT FIGURE 5 
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Discussion  
The main findings of this research are that, for both types of medication assessed (SSRIs and 
AAs), pharmacological treatment significantly reduced sexual preoccupation and hypersexual 
behaviour, with declines in preoccupation and hypersexual behaviour just one month after 
medication – replicating the results of Kafka and Prentky (1992) who reported significant 
declines by week four of SSRI medication for individuals with paraphilic and non-paraphilic 
sexual addictions. In the current study, reductions continued at three months and six months, 
levelling off with the SSRIs but continuing to show a steady decline with the AAs.  
These reductions in the clinical measures of hypersexual disorder, captured by the 
consulting psychiatrist as part of patients’ ongoing medical treatment, were confirmed with 
the psychometric measure of sexual compulsivity, which were collated independently of the 
clinical measures. Reductions were such that the mean levels of sexual compulsivity for the 
present sample six months’ post medication, were similar to those reported elsewhere for the 
general population in the prison (see Winder et al., 2013), and equivalent to those reported by 
UK male university students (Winder, Lievesley & Day, in prep.). Whilst a mean score of 1.0 
with the sexual compulsivity measure would indicate an individual who is not reporting 
problems with sexual urges impacting upon their life in any domain, this level may be an 
over-optimistic goal for sexually preoccupied prisoners, and equivalence with an age-
appropriated non-offending norm would be the preferred match.  
It should be noted that the medication to manage sexual arousal is not designed to 
eradicate all sexuality from individuals (although some prisoners, particularly those with a 
long history of time in prison for sexual offences, have reported that this is what they are 
hoping for – see Lievesley et al., 2014). However, both healthy sexual functioning, together 
with an emotionally intimate relationship with another, address two of the principal dynamic 
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risk factors for sexual recidivism. This is important if we are viewing the use of medication 
from the more risk-oriented stance of the Risk, Need and Responsibility model (Andrews, 
Bonta & Hoge, 1990; Andrews, Bonta & Wormith, 2011). Having a healthy sexual 
relationship and a close emotional relationship also fit with the Good Lives Model (Ward, 
2002a; 2002b; Ward & Brown, 2004), whereby healthy sexual expression is recognised as a 
primary human good, and if achieved is hypothesised to reduce recidivism.   
In terms of the types of medication utilised to manage sexual arousal, it is important to 
reiterate that SSRIs are not part of the current UK NICE guidelines for the treatment of 
hypersexuality. One of the difficulties is the lack of randomised control trial (an attempt at 
this was made by Grubin in 2006 but had to be abandoned due to an inadequate sample). The 
second challenge highlighted by NICE (2015) is the lack of comparison data between AAs 
and SSRIs. The present study seeks to address this need.   
The current study also allowed a description of the prisoners perceived as struggling to 
cope with hypersexual disorder: referrals were a particularly high (static) risk, sexually 
preoccupied group with a greater prevalence of dynamic risk factors being ‘strongly present’ 
in these individuals (in comparison with prisoners with sexual convictions in the UK 
generally – see Winder et al., 2013). The results also indicated the presence of the dynamic 
treatment needs of ‘sexual preoccupation’ (in the offence chain), ‘poor problem solving’, 
‘sexual preoccupation’ (generally in life), ‘lack of an emotionally intimate relationship’, 
‘feelings of inadequacy’ and ‘sexual preference for children’. 
Hypersexuality has also been demonstrated as being comorbid with a number of 
psychiatric conditions, including mood and anxiety disorders, substance-abuse (Raymond, 
Coleman, & Miner, 2003; Kafka & Prentky, 1994; Reid, 2007), and poor occupational and 
interpersonal functioning (Black, Kehrberg, Flumerfelt, & Schlosser, 1997). Future papers 
will examine several of these co-morbidities, as well as reporting further on reported side 
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effects of each type of medication (but see Lievesley et al., 2014, for a summary of side 
effects reported by patients prescribed SSRI medication for hypersexuality). There are 
additional health concerns presented by hypersexuality: for example, excessive masturbation 
may occur, resulting in genital soreness (Winder, 2016), thus hypersexual disorder can be 
problematic in impacting upon the physical and mental wellbeing of self and others. 
 A further factor of note was that forty-four percent of prisoners referred for medication 
to manage sexual arousal were borderline/intellectually disabled. This is out of proportion 
with the figures of approximately one in four of the prisoners at this prison being 
borderline/intellectually disabled (K. Hocken, personal communication, February 13, 2016). 
Suggested explanations for this are that these prisoners may have greater difficulty managing 
their hypersexuality (potentially they have less opportunities to distract themselves, for 
example, by reading or writing), or that they are more acquiescent to suggestions for referral 
by prison staff (given acquiescence is associated with intellectual disability; Gudjonsson, 
1990). They may also be more accepting of medication as a method of treatment, or their 
struggle to manage their hypersexuality may be less well hidden than by other prisoners. 
There were few differences in client characteristics and response to treatment between 
borderline and ID referrals and non-intellectually disabled referrals for the pharmacological 
treatment of hypersexual disorder in this UK sample (see Hocken, Winder, Lievesley, 
Norman & Elliott, 2015). Further exploratory work is underway to ascertain the reasons 
behind the relatively high proportion of borderline/ID referrals.   
A primary limitation of this evaluation is the use of self-report data, with resultant 
questions about its validity and reliability. However, the data were collated on different 
occasions and within different contexts (clinical data were collected by the prison psychiatrist; 
sexual compulsivity data were collected by the research team). Moreover, participants were 
not reminded of their previous responses (collated 4-12 weeks previously), nor did the 
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research team review data from previous instances. The clinical data and psychometric data 
demonstrated good triangulation, and the robustness of the data has been underpinned by a 
qualitative study comprising interviews with participants (see Lievesley et al., 2014).  
A further limitation of the analyses presented here are the aggregation of datasets 
(those service users prescribed AAs were presented in the same experimental group as service 
users prescribed both AAs and SSRIs). Only two prisoners were prescribed GnRH and thus it 
was not feasible to conduct an analysis of these data. Data from two of the three medications 
groups (SSRIs, AAs, SSRIS/AAs) were aggregated (the SSRIs plus AAs were combined with 
the AAs only) partly because the focus of the evaluation was to consider if SSRIs 
significantly reduced hypersexuality. It was therefore important to consider the SSRIs group 
as a standalone experimental group and to ascertain how they performed compared to 
individuals taking AAs (whether or not there was any additional medication). AAs have 
already been tested as per NICE (2015) guidelines and their anti-libidinal effect demonstrated 
sufficiently. It was also the case that the AAs only group was considerably smaller than the 
other two experimental groups so meaningful statistical analysis could not be conducted, 
however a future study (with a larger sample) should be able to extricate all three of these 
groups and provide inter-group comparisons.    
In addition, it is recognised that the RM2000 has not been validated for those with ID, 
and so results of this assessment should be taken with a degree of caution (Pryboda, Tully & 
Brown, 2015). It is acknowledged that objective measures such as the Penile Plethysmograph 
(PPG) may add a level of reliability to the research (Murphy, Ranger, Stewart, Dwyer & 
Fedoroff, 2015); however, the PPG is an invasive procedure that is highly labour-intensive 
(Laws, 2003), has several limitations itself and is not available for use in this prison 
establishment. The use of a behavioural/objective measure is being considered for the future 
as it would also help to reduce the potential for impression management by participants. 
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Impression management is currently assessed using psychometric scales that will be reported 
on in a future publication (Lievesley et al, in prep.). 
A further limitation of this research is the lack of a control group – this is now being 
addressed and the results will be presented in a future publication, once sufficient data are 
available. It is also recognised that this research is currently limited to one site, which may 
have implications for the findings (such as over-estimating the magnitude of the results and 
results not generalising over other prison populations). This is currently being addressed as 
the research is now being extended to seven other prison sites within the UK. Future research 
should also explore the differences in treatment response between new and repeat sexual 
offenders. 
It is recognised that completing an SOTP course may be a confounding variable to the 
medication effects, and this is especially difficult to extricate from the data since 83% of the 
sample had already completed an SOTP, whilst the majority of the remaining were highly 
likely to either have commenced (but not yet finished an SOTP) or to be on the waiting list 
(given the prison where this evaluation was based only accepts individuals willing to undergo 
treatment in the SOTP). In future research, it may be possible to evaluate the impact of 
medication where no treatment has been available (or perhaps more realistically, before 
treatment has been commenced) but this is not feasible at the current time.  
There is an additional confounding factor with regard to type of medication offered to 
individuals in the prescribing of either SSRIs or AAs. Prescribing practice is based on the 
clinical judgement of the psychiatrist, underpinned by dosage and prescribing protocols 
prepared by Grubin (2015). Typically, prisoners will be prescribed SSRIs as a starting point, 
but if these are not deemed to be reducing hypersexuality (as assessed by the psychiatrist and 
taking into account reports from the patient in addition to any other input from, for example, 
psychologists), the patient will be moved on to AAs.  
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Conclusions 
Both types of pharmacological treatment (SSRIs and AAs) significantly reduced hypersexual 
behaviour and sexual preoccupation. The same significant reduction was demonstrated from 
pre to post pharmacological treatment in levels of sexual compulsivity. These findings 
indicate that both SSRIs and AAs can work effectively as medication to manage sexual 
arousal and hypersexual disorder. This supports the decision made by the HMPPS to make 
MMSA available across the majority of the UK prison estate from 2016. However, ongoing 
evaluation work, including a control group study, an analysis of the impact of each of the 
three main medication groups (SSRIs, AAs, and SSRIS with AAs), an extension of the 
evaluation into prisons with open conditions, as well as following up medicated individuals in 
the community, are an important part of this process. 
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Figure Captions 
Figure 1: Mean Sexual Compulsivity Scores for participants taking (i) SSRIs and (ii) AAs to 
reduce sexual preoccupation pre-medication and three months post-medication. 
 
Figure 2: Number of days masturbated in previous week for participants taking (i) SSRIs and 
(ii) AAs 
 
Figure 3: Amount of time currently spent thinking about sex for participants taking (i) SSRIs 
and (ii) AAs 
 
Figure 4: Strength of sexual urges and fantasies for participants taking (i) SSRIs and (ii) AAs 
 
Figure 5: Ability to distract from sexual thoughts for participants taking (i) SSRIs and (ii) 
AAs 
 
 
